Psoriasis

Source: www.ncbi.nlm.nih.gov --- 14 days ago
Related Articles Infliximab-induced pityriasis lichenoides chronica in a patient with Psoriasis. J Eur Acad Dermatol Venereol. 2008 Aug 1; Authors: Newell E, Jain S, Stephens C, Martland G PMID: 18680531 [PubMed - as supplied by publisher] ...

Source: www.ncbi.nlm.nih.gov --- 19 days ago
Related Articles Recurrent Varicella in an Adult Psoriasis Patient Treated with Etanercept. Dermatology. 2008 Jul 31;217(3):260-261 Authors: Becart S, Segaert S PMID: 18667825 [PubMed - as supplied by publisher] ...

Source: www.ncbi.nlm.nih.gov --- 12 days ago
Related Articles Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus. Dermatology. 2008 Aug 6;217(3):268-275 Authors: Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Giannetti A, Gniadecki R, Katsambas A, Langley R, Mrowietz U, Ogilvie A, Ortonne JP, Reider N, Saurat JH Background/Aims: Infliximab has been approved for the treatment of chronic plaque Psoriasis for only a few years. As physicians gain confidence in initiating and maintaining this therapy, guidance on the management of patients beyond several months or years is needed. To date, there is little or no information about the long-term management in clinical trials or guidelines. Methods: Here we report on the key aspects related to the use of infliximab for the treatment of Psoriasis. The data presented here were derived using a modified Delphi survey to obtain a consensus opinion of 11 dermatologists from Europe and Canada experienced in long-term therapy with infliximab. Results/Conclusion: The Delphi participants reviewed several important topics related to biological therapy and infliximab. This paper is not intended to provide a recommendation on all practical aspects related to biological therapy; it has rather been written to provide useful and practical information on the 'best practice' use of infliximab. PMID: 18685261 [PubMed - as supplied by publisher] ...

Source: www.ncbi.nlm.nih.gov --- 1 day ago
Related Articles Vogt-koyanagi-harada syndrome associated with Psoriasis and autoimmune thyroid disease. Acta Derm Venereol. 2008;88(4):397-8 Authors: Kluger N, Mura F, Guillot B, Bessis D PMID: 18709315 [PubMed - in process] ...

Source: www.ncbi.nlm.nih.gov --- 7 days ago
Related Articles Targeting tumor necrosis factor alpha in Psoriasis and psoriatic arthritis. Expert Opin Ther Targets. 2008 Sep;12(9):1085-96 Authors: Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G BACKGROUND: Psoriasis is an immune-mediated chronic inflammatory disease triggered and maintained by inflammatory mediators, including TNF-alpha. OBJECTIVE/METHODS: To summarize the role of anti-TNF-alpha agents Psoriasis therapy, focusing on the mechanisms and biological pathways involved, by reviewing relevant literature. RESULTS/CONCLUSIONS: The three TNF-alpha antagonists currently available (etanercept, infliximab and adalimumab) are effective in the therapy of Psoriasis and psoriatic arthritis. Certolizumab pegol and golimumab are TNF-alpha inhibitors not approved for therapy of Psoriasis yet. In addition to neutralizing soluble TNF-alpha, TNF-alpha blockers bind to membrane TNF-alpha and change the behavior of TNF-alpha-expressing cells, resulting in hastened cell cycle arrest and apoptosis, and suppression of cytokine production. TNF-alpha blockers may also affect adaptive immune responses by reducing T helper cell (Th)1 and Th17 responses, and favoring the development of T-regulatory cells. TNF-alpha antagonists can regulate differentiation and activation of osteoclasts, thus reducing bone destruction in psoriatic arthritis. Anti-TNF-alpha agents differ in their pharmacokinetics and pharmacodinamic properties, which is reflected ...

Source: www.ncbi.nlm.nih.gov --- 10 days ago
Related Articles Epidermal Vascular Endothelial Growth Factor Production Is Required for Permeability Barrier Homeostasis, Dermal Angiogenesis, and the Development of Epidermal Hyperplasia. Implications for the Pathogenesis of Psoriasis. Am J Pathol. 2008 Aug 7; Authors: Elias PM, Arbiser J, Brown BE, Rossiter H, Man MQ, Cerimele F, Crumrine D, Gunathilake R, Choi EH, Uchida Y, Tschachler E, Feingold KR Primary abnormalities in permeability barrier function appear to underlie atopic dermatitis and epidermal trauma; a concomitant barrier dysfunction could also drive other inflammatory dermatoses, including Psoriasis. Central to this outside-inside view of disease pathogenesis is the epidermal generation of cytokines/growth factors, which in turn signal downstream epidermal repair mechanisms. Yet, this cascade, if sustained, signals downstream epidermal hyperplasia and inflammation. We found here that acute barrier disruption rapidly stimulates mRNA and protein expression of epidermal vascular endothelial growth factor-A (VEGF-A) in normal hairless mice, a specific response to permeability barrier requirements because up-regulation is blocked by application of a vapor-impermeable membrane. Moreover, epidermal vegf(-/-) mice display abnormal permeability barrier homeostasis, attributable to decreased VEGF signaling of epidermal lamellar body production; a paucity of dermal capillaries with reduced vascular permeability; and neither angiog ...

Source: www.ncbi.nlm.nih.gov --- 9 days ago
Related Articles Rapid Onset and Fatal Outcome of Two Squamous Cell Carcinomas of the Genitalia in a Patient Treated with Etanercept for Cutaneous Psoriasis. Dermatology. 2008 Aug 7;217(3):284-285 Authors: Comte C, Guilhou JJ, Guillot B, Dereure O PMID: 18688171 [PubMed - as supplied by publisher] ...

Source: www.prweb.com --- 1 day ago
Psoriasis Cure Now today announced that participants from half the states are now registered for the second annual "Short Sleeve Days," a national Psoriasis education and awareness event, to be held September 12-14, 2008. (PRWeb Aug 19, 2008) Read the full story at http://www.prweb.com/releases/2008/08/prweb1221104.htm ...

Source: health.discovery.com --- 9 days ago
Visit the Skin Health Center to learn what causes this chronic skin disorder and how to treat it. ...

Source: www.prnewswire.com --- 9 days ago
...

Source: www.businesswire.com --- 1 day ago
BALLERUP, Danemark--(BUSINESS WIRE)--Xamiol® – Le nouveau médicament de LEO Pharma pour le traitement du Psoriasis du cuir ...

Source: www.moreover.com --- 11 days ago
Contract Pharma Aug 8 2008 11:22PM GMT ...

Source: www.moreover.com --- 10 days ago
TheStar.com.my Aug 10 2008 5:16AM GMT ...

Source: www.simpy.com --- 9 days ago
--> Tagged by douglask1 under %s , ...

Source: content.karger.com --- 13 days ago
Dermatology 2008;217:284-285 (DOI:10.1159/000150603) ...

Source: www.24-7pressrelease.com --- 6 days ago
August is Psoriasis Awareness Month, As a way to celebrate this month we are offering employers half off on ads they post on the 15th, if they mention this press release. We encourage these savings to be donated to the National Psoriasis Foundation, http://www.Psoriasis.org/donate/. ...

Source: content.karger.com --- 7 days ago
Dermatology 2008;217:268-275 (DOI:10.1159/000149970) ...

Source: ace.mu.nu --- 7 days ago
Another training camp religious school in South Waziristan. AP reported 14 dead, other sources say more. An intelligence official in South Waziristan, who declined to be identified, told Reuters that at least four missiles were fired from across the border... ...

Source: blog.hypnosisdownloads.com --- 22 days ago
Full hypnosis download Psoriasis treatment - in production Years ago I recall watching The Singing Detective, a television serial about a mystery writer called Philip Marlow. Marlow was in hospital suffering from an extreme episode of Psoriasis, or ‘psoriatic arthopathy’, a chronic condition of the skin and joints. He was covered in sores and clearly deeply [...] ...